MedTrace Logo

Histamine as a Molecular Transducer of Adaptation to Exercise

NCT05206227 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-23

No results posted yet for this study

Summary

This study is investigating the role of histamine in generating adaptation to exercise

Conditions

  • Postexercise Hypotension

Interventions

BEHAVIORAL

Aerobic Exercise

Subjects will complete a single bout of aerobic exercise.

DRUG

alpha-FMH

Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.

BEHAVIORAL

Resistance and Aerobic Exercise

Subjects will complete bouts of resistance and aerobic exercise.

DRUG

Antihistamine

Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.

Sponsors & Collaborators

  • University of Oregon

    lead OTHER

Principal Investigators

  • John R Halliwill, PhD · University of Oregon

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2025-12-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05206227 on ClinicalTrials.gov